Cancer Radiation Therapy Market: Rising Cancer Incidence to Drive Market Growth to US$ 136.16 Billion by 2031.

As per the latest market research by Business Market Insights (BMI), the research report" Cancer Radiation Therapy Market Size and Forecast (2025–2031)" forecasts how the market is set to surge 134.7% by 2031. The global cancer radiation therapy market is a vital part of oncology care, covering external beam and internal radiation therapies across multiple cancer types. Market growth is driven by rising cancer incidence, aging populations, and wider use of radiation in combination treatments. Advancements such as Intensity-Modulated Radiation Therapy (IMRT), Image-Guided Radiation Therapy (IGRT), Stereotactic Body Radiation Therapy (SBRT), and proton therapy are improving precision, safety, and clinical outcomes worldwide.

The report forecasts the market to expand from US$ 57.88 Billion in 2024 to US$ 136.16 Billion, registering a robust CAGR of 13.00% over the 2025–2031 period.

The global cancer radiation therapy market represents a critical segment of oncology care, encompassing external beam and internal radiation therapies used across a wide range of cancer types. Radiation therapy remains a cornerstone treatment due to its effectiveness in tumor control, organ preservation, and symptom management. Market growth is supported by rising global cancer burden, expanding aging populations, and increasing integration of radiation therapy into multimodal treatment approaches. Technological progress, including image-guided, intensity-modulated, stereotactic, and proton-based therapies, continues to improve clinical outcomes and treatment safety. Additionally, growing investments in cancer care infrastructure, rising awareness, and improving access to advanced radiotherapy systems in developing regions are strengthening market expansion worldwide.

Overview of report findings

Market Growth

The cancer radiation therapy market is projected to grow from US$ 57.88 Billion in 2024 to US$ 136.16 Billion by 2031, registering a compound annual growth rate (CAGR) of 13.0% between 2025 and 2031.

The global cancer radiation therapy market is a vital part of oncology care, covering external beam and internal radiation therapies across multiple cancer types. Market growth is driven by rising cancer incidence, aging populations, and wider use of radiation in combination treatments. Advancements such as Intensity-Modulated Radiation Therapy (IMRT), Image-Guided Radiation Therapy (IGRT), Stereotactic Body Radiation Therapy (SBRT), and proton therapy are improving precision, safety, and clinical outcomes worldwide.

Rising Cancer Incidence

The increasing incidence of cancer globally is one of the most significant drivers of the radiation therapy market. Factors such as aging populations, sedentary lifestyles, tobacco and alcohol consumption, environmental exposure, and improved diagnostic capabilities are contributing to higher cancer detection rates across regions. As cancer cases rise, demand for effective and scalable treatment modalities increases, positioning radiation therapy as a core component of oncology care. Radiation therapy is widely used across curative, adjuvant, and palliative settings for solid tumors, including breast, lung, prostate, head and neck, and colorectal cancers. Its ability to target tumors precisely while preserving surrounding healthy tissue makes it a preferred option either as a standalone treatment or in combination with surgery and chemotherapy. The growing patient pool directly increases utilization rates of radiotherapy equipment, treatment planning systems, and related services, thereby accelerating market growth globally.

Shift Toward Personalized & Precision Medicine

The transition toward personalized and precision medicine is transforming cancer treatment and strongly driving the radiation therapy market. Advances in imaging, genomics, artificial intelligence, and data analytics enable clinicians to tailor radiation dose, delivery technique, and treatment schedules to individual patient and tumor characteristics. Technologies such as Intensity-Modulated Radiation Therapy (IMRT), Image-Guided Radiation Therapy (IGRT), and Stereotactic Body Radiation Therapy (SBRT) allow highly conformal dose delivery with minimal exposure to surrounding healthy tissue. Personalized treatment planning improves therapeutic outcomes, reduces side effects, and enhances patient quality of life, increasing clinician and patient preference for advanced radiotherapy. As healthcare systems increasingly emphasize value-based care and outcome optimization, adoption of precision radiation technologies continues to rise, supporting sustained market expansion.

Geographic Insights

North America leads the global cancer radiation therapy market due to high cancer prevalence, strong healthcare infrastructure, and early adoption of advanced radiotherapy technologies. The region benefits from widespread availability of Intensity-Modulated Radiation Therapy (IMRT), Image-Guided Radiation Therapy (IGRT), proton therapy, and stereotactic systems. Favorable reimbursement frameworks, high healthcare spending, and the presence of leading oncology equipment manufacturers further support market dominance.

Europe holds the second-largest share of the cancer radiation therapy market, supported by rising cancer incidence, well-established public healthcare systems, and strong clinical adoption of advanced radiation techniques. Countries such as Germany, France, and the United Kingdom have extensive radiotherapy infrastructure and national cancer control programs. Continuous technology upgrades, research initiatives, and increasing focus on precision oncology sustain steady market growth across the region.

Asia Pacific is the fastest-growing region in the cancer radiation therapy market due to rapidly increasing cancer burden, large patient populations, and expanding access to oncology care. Improving healthcare infrastructure, rising healthcare investments, and growing adoption of advanced radiotherapy systems in China, India, and Southeast Asia are key growth drivers. Additionally, increasing awareness and government-led cancer initiatives are accelerating market expansion.

Segmentation

• By type, the cancer radiation therapy market is segmented into external beam radiation therapy and internal beam radiation therapy. The external beam radiation therapy segment dominated the market in 2024. Due to its widespread availability, precision targeting, noninvasive nature, and effectiveness in treating diverse cancers, it is the preferred choice across global oncology practices.
• In terms of cancer type, the cancer radiation therapy market is segmented into lung cancer, breast cancer, colorectal cancer, prostate cancer, head & neck cancer, cervical cancer, and others. The lung cancer segment dominated the market in 2024. Due to its high incidence, strong link with smoking and pollution, late‑stage diagnoses, and reliance on advanced radiation techniques, it is the most treated cancer type globally.
• Based on end user, the cancer radiation therapy market is segmented into hospitals, specialty clinics, ambulatory and radiotherapy centers, and academic and research institutes. The hospitals segment dominated the market in 2024. Hospitals dominated the market since they provide comprehensive cancer care, advanced radiation infrastructure, skilled oncologists, and integrated treatment pathways, making them the primary setting for delivering radiation therapy services.

Competitive Strategy & Development

Key Players: The cancer radiation therapy market is populated by several key players, each contributing to its growth and innovation. Some prominent players are:

1. Siemens Healthineers
2. Accuray Incorporated
3. Elekta
4. Brainlab AG
5. RefleXion
6. Hitachi Ltd
7. IBA Worldwide
8. GT Medical Technologies, Inc. 
9. Mevion Medical Systems
10. Theragenics Corporation

Trending Topics: Cancer Hormone Therapy Market, Cancer Targeted Therapy Market, Cancer Chemotherapy Market, Cancer Therapeutics Market.

Global Headlines

• Accuray announced launch of Accuray Stellar Solution – in September 2025, Accuray Incorporated announced that the company has launched Accuray Stellar Solution in United States.
• Elekta announced launch of Elekta Evo – in November 2025, Elekta announced the introduction of Elekta Evo, an advanced AI-enabled CT-Linac, aimed at enhancing India's cancer care through real-time adaptive radiotherapy. The technology, showcased at the Association of Radiation Oncologists of India conference (AROICON), seeks to personalize cancer treatment based on real-time tumor changes to address the country's rising cancer burden.

Conclusion

The global cancer radiation therapy market is positioned for sustained growth, driven by rising cancer incidence, continuous technological advancements, and increasing integration of radiation therapy into comprehensive cancer care pathways. Innovations in precision and personalized treatment approaches are improving clinical outcomes while minimizing treatment-related complications, reinforcing the role of radiotherapy across curative and palliative settings. Strong market presence in North America and Europe ensures stable demand, while rapid healthcare development in Asia Pacific is creating significant growth opportunities. Ongoing investments in oncology infrastructure, supportive government initiatives, and expanding access to advanced radiation technologies are expected to further strengthen market expansion, making radiation therapy a critical and evolving component of global cancer management.